{"groups":[{"description":"Participants with TCR MM who initiated elranatamab (PF-06863135) following TCR eligibility in study C1071003 (NCT04649359) were included.","id":"FG000","title":"Study C1071003 Cohort A"},{"description":"Participants with RW TCR MM who initiated standard of care treatment following TCR eligibility between 16-Nov-2015 and 31-Mar-2022 identified from COTA database were included.","id":"FG001","title":"COTA Cohort"},{"description":"Participants with RW TCR MM who initiated standard of care treatment following TCR eligibility between 16-Nov-2015 and 31-Mar-2022 identified from Flatiron Health database were included.","id":"FG002","title":"Flatiron Health Cohort"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"123"},{"groupId":"FG001","numSubjects":"233"},{"groupId":"FG002","numSubjects":"152"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"123"},{"groupId":"FG001","numSubjects":"233"},{"groupId":"FG002","numSubjects":"152"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Index date was defined as the date of initiation of the first regimen after TCR MM eligibility. Only participants with an index date between 16-Nov-2015 and 31-Mar-2022 were selected. Participants were observed from the index date to the earliest of death, or the latest available participants record, whichever occurred first.","recruitmentDetails":"This retrospective cohort study included triple-class refractory (TCR) multiple myeloma (MM) participants who initiated elranatamab in study C1071003 (NCT04649359) and 2 cohorts of real-world (RW) TCR MM participants who initiated standard of care (SOC) treatment identified from Flatiron Health and COTA databases as external control arms for Study C1071003."}